Abstract | OBJECTIVE: METHOD: The double-blind, randomized, placebo-controlled trial used the sequential parallel comparison design. Outpatients with SSRI-resistant MDD (DSM-IV criteria) received L-methylfolate 15 mg/d for 60 days, placebo for 30 days followed by L-methylfolate 15 mg/d for 30 days, or placebo for 60 days. The effects of baseline levels of select biological and genetic markers individually and combined on treatment response to L-methylfolate versus placebo were evaluated; the primary response measure was the 28-Item Hamilton Depression Rating Scale (HDRS-28). The first patient was enrolled July 14, 2009, and the last patient completed April 28, 2011. RESULTS: CONCLUSIONS: TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00955955.
|
Authors | George I Papakostas, Richard C Shelton, John M Zajecka, Teodoro Bottiglieri, Joshua Roffman, Clair Cassiello, Stephen M Stahl, Maurizio Fava |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 75
Issue 8
Pg. 855-63
(Aug 2014)
ISSN: 1555-2101 [Electronic] United States |
PMID | 24813065
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © Copyright 2014 Physicians Postgraduate Press, Inc. |
Chemical References |
- Aldehydes
- Biomarkers
- Serotonin Uptake Inhibitors
- Tetrahydrofolates
- S-Adenosylmethionine
- C-Reactive Protein
- S-Adenosylhomocysteine
- 4-hydroxy-2-nonenal
- 5-methyltetrahydrofolate
|
Topics |
- Adolescent
- Adult
- Aged
- Aldehydes
(blood)
- Biomarkers
(blood)
- C-Reactive Protein
- Depressive Disorder, Treatment-Resistant
(blood, drug therapy, genetics)
- Drug Therapy, Combination
- Female
- Genotype
- Humans
- Male
- Middle Aged
- S-Adenosylhomocysteine
(blood)
- S-Adenosylmethionine
(blood)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Tetrahydrofolates
(genetics, therapeutic use)
- Young Adult
|